These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7088206)

  • 41. The influence of pretreatment on cure rates of Helicobacter pylori eradication.
    Janssen MJ; Laheij RJ; Jansen JB; de Boer WA
    Neth J Med; 2004 Jun; 62(6):192-6. PubMed ID: 15460498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
    Avidan B; Melzer E; Keller N; Bar-Meir S
    Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety profile of De-Nol.
    Bader JP
    Digestion; 1987; 37 Suppl 2():53-9. PubMed ID: 3622947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological properties of colloidal bismuth subcitrate (CBS, DE-NOL).
    Wieriks J; Hespe W; Jaitly KD; Koekkoek PH; Lavy U
    Scand J Gastroenterol Suppl; 1982; 80():11-6. PubMed ID: 6962539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 46. Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication.
    Treiber G; Walker S; Klotz U
    Arzneimittelforschung; 1997 Jan; 47(1):47-50. PubMed ID: 9037444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
    Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA
    Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414
    [No Abstract]   [Full Text] [Related]  

  • 48. [Gastropharm in the treatment of peptic ulcer].
    Potashov LV; Sedykh VM; Figurina TD; Sonina SI; Kudrevatykh IP
    Klin Med (Mosk); 1981 Feb; 59(2):50-3. PubMed ID: 7289486
    [No Abstract]   [Full Text] [Related]  

  • 49. [Therapy of peptic ulcer. Bismuth salts].
    Börsch G
    Verh Dtsch Ges Inn Med; 1988; 94():284-92. PubMed ID: 3061197
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of peptic ulcer with gastrozepin].
    Grigor'ev PIa; Khar'kovskiĭ NN; Elina NA; El'tsova NB; Elisova NV
    Sov Med; 1984; (1):48-51. PubMed ID: 6546622
    [No Abstract]   [Full Text] [Related]  

  • 51. Colloidal bismuth subcitrate as coated tablets: four times versus twice daily dosage in duodenal ulcer.
    Lazzaroni M; Parente F; Prada A; Bianchi Porro G
    Scand J Gastroenterol Suppl; 1986; 122():51-3. PubMed ID: 3535022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of repeated colloidal bismuth subcitrate treatment on the response of the rat gastric mucosa to the presence of luminal ethanol.
    Hinsull SM; Bellamy D
    Gut; 1990 Apr; 31(4):389-96. PubMed ID: 2338263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
    Gabryelewicz A
    J Physiol Pharmacol; 1996 Mar; 47(1):51-8. PubMed ID: 8777307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Helicobacter pylori eradication: triple therapy versus dual therapy].
    Dammann HG
    Fortschr Med; 1996 Feb; 114(4):34-8. PubMed ID: 8852685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacotherapy of peptic ulcer].
    Ryss ES
    Klin Med (Mosk); 1980 Jan; 58(1):16-21. PubMed ID: 6988638
    [No Abstract]   [Full Text] [Related]  

  • 56. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
    Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
    Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
    Hunt RH
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):36S-40S; discussion 40S-43S. PubMed ID: 9127625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection.
    Tucci A; Poli L; Gasperoni S; Varoli O; Paparo GF; De Giorgio R; Stanghellini V; Corinaldesi R
    Ital J Gastroenterol; 1994 Apr; 26(3):107-10. PubMed ID: 8061335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; problems on standardization of the appropriate time for the withdrawal of anti-ulcer agents].
    Takemoto T; Yanai H
    Nihon Rinsho; 1988 Jan; 46(1):133-9. PubMed ID: 3373746
    [No Abstract]   [Full Text] [Related]  

  • 60. The modern treatment of peptic ulceration.
    Pounder RE
    Practitioner; 1981 Oct; 225(1360):1371-6. PubMed ID: 7329928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.